Orchestra BioMed Holdings, Inc. (OBIO)

In the past six months, Orchestra BioMed Holdings, Inc. experienced a share price decline of 22.86% between January 2, 2025, and December 31, 2025. On December 10, 2025, TD Cowen initiated coverage of OBIO with a "Buy" recommendation, with an average one-year price target of $13.60/share. On January 12, 2026, Orchestra BioMed announced it expects to receive up to $21 million in cash proceeds following the acquisition of its strategic investment, Vivasure Medical, by Haemonetics Corporation. The company also highlighted strategic and financing developments, including its Q3 2025 financial results, which reported gross proceeds and committed capital of $147.6 million to extend its cash runway into Q4 2027. Presentations on AVIM Therapy and Virtue SAB programs were made at the ICI Meeting on December 8, 2025.

Due to the limited availability of data, it is challenging to create a reliable seasonal profile for Orchestra BioMed Holdings, Inc. products and services. However, a seasonal analysis over the past four years suggests a potential seasonal pattern with a "Buy Date" of September 2 and a "Sell Date" of January 22. This timeframe has historically resulted in a geometric average return of 10.6% above the S&P 500 Total Return Index, with positive results in all four periods.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company operates within the Healthcare sector, specifically in Biotechnology, Healthcare Equipment & Supplies, and Medicinal Chemicals and Botanical Products. Its major product candidates include Atrioventricular Interval Modulation (AVIM) Therapy / BackBeat Cardiac Neuromodulation Therapy (CNT), Virtue Sirolimus AngioInfusion Balloon (SAB), Cardiac Neuromodulation Therapy for heart failure (CNT-HF), FreeHold devices, and the Pure-Vu system.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States and is headquartered in New Hope, Pennsylvania. Through its strategic collaborations with global medical device companies like Medtronic and Terumo Corporation, the company's product development and commercialization efforts have a broader international reach.

In the past year, Orchestra BioMed Holdings, Inc. has generally maintained a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" based on reports from 8 Wall Street analysts. Positive corporate events, such as strategic partnerships and significant financing, have contributed to a strong foundation for future growth. However, the company's overall stock score has been impacted by weak financial performance, characterized by high leverage and negative profit margins.

The ownership structure of Orchestra BioMed Holdings, Inc. is a mix of institutional, retail, and individual investors. Key institutional shareholders include RTW Investments, LP, Perceptive Advisors LLC, Vanguard Group Inc., Alyeska Investment Group, L.P., Pathstone Holdings, LLC, Affinity Asset Advisors, LLC, and BlackRock, Inc. Retail investors hold a substantial stake, and David Hochman, the CEO, holds 0.8% of the shares. Insider buying activity has been observed in the past three months.